Evaluation of low‐dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: A pilot study

Fang, Wei-Cheng; Chiu, Szu-Hao; Lin, Sheng-Yiao; Huang, Shu‐Mei; Lan, Cheng‐Che E.

doi:10.1111/phpp.12661

Cited by 8 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we treated our patients with a combination of low‐dose tofacitinib and 308‐nm excimer light, which resulted in a higher mean reduction in VES and higher repigmentation rates than previously reported 5 (32.7% vs. 24.9% and 2% vs. 14.4%, respectively). All patients also showed at least Grade 2 repigmentation (>25%) compared with the previous NB‐UVB study 5 . Additionally, lesions in areas not exposed to sunlight also showed response to the treatment.…”

Section: Parameter Patient 1 2mentioning

confidence: 90%

“…All patients also showed at least Grade 2 repigmentation (>25%) compared with the previous NB-UVB study. 5 Additionally, lesions in areas not exposed to sunlight also showed response to the treatment.…”

Section: Supporting Informationmentioning

confidence: 99%

“…We previously reported that low‐dose tofacitinib with narrowband ultraviolet B (NB‐UVB) therapy for 16 weeks is insufficient to treat refractory vitiligo, and only one out of four patients showed marked repigmentation 5 . In the current study, we treated our patients with a combination of low‐dose tofacitinib and 308‐nm excimer light, which resulted in a higher mean reduction in VES and higher repigmentation rates than previously reported 5 (32.7% vs. 24.9% and 2% vs. 14.4%, respectively). All patients also showed at least Grade 2 repigmentation (>25%) compared with the previous NB‐UVB study 5 .…”

Section: Parameter Patient 1 2mentioning

confidence: 99%

“…Low‐dose (5 mg daily) tofacitinib has shown efficacy for severe alopecia areata, which shares a mechanistic link with vitiligo 4 . We previously reported that low‐dose tofacitinib with narrowband ultraviolet B (NB‐UVB) therapy for 16 weeks is insufficient to treat refractory vitiligo, and only one out of four patients showed marked repigmentation 5 . In the current study, we treated our patients with a combination of low‐dose tofacitinib and 308‐nm excimer light, which resulted in a higher mean reduction in VES and higher repigmentation rates than previously reported 5 (32.7% vs. 24.9% and 2% vs. 14.4%, respectively).…”

Section: Parameter Patient 1 2mentioning

confidence: 99%

See 3 more Smart Citations

Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo

Fang

Lin

Huang

et al. 2022

Clinical and Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Parameter Patient 1 2mentioning

confidence: 90%

Section: Supporting Informationmentioning

confidence: 99%

Section: Parameter Patient 1 2mentioning

confidence: 99%

Section: Parameter Patient 1 2mentioning

confidence: 99%

See 2 more Smart Citations

Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo

Fang

Lin

Huang

et al. 2022

Clinical and Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Outside the extension study, one other cohort study allowed optional phototherapy and another cohort study did not discuss regimens for adjuvant phototherapy. 39,41 Treatment regimens also varied, and some studies lacked clarity on the location/vitiligo type. Indeed, of the seven cohort studies, only two controlled for vitiligo type.…”

Section: Jak Inhibitorsmentioning

confidence: 99%

A review of JAK and IL‐23 inhibitors to treat vitiligo

et al. 2023

View full text Add to dashboard Cite

Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%–2% of the global population. Despite its well‐understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first‐line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associated with significant adverse events or can be time‐consuming. Therefore, biologics should be explored as a potential treatment for vitiligo. There are currently limited data for the use of JAK and IL‐23 inhibitors for vitiligo. A total of 25 studies were identified in the review. There is promising evidence regarding the use of JAK and IL‐23 inhibitors for the treatment of vitiligo.

show abstract

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis

Huang,

Hu,

Fan

et al. 2024

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Although several case reports and small clinical trials have reported promising outcomes with Janus kinase (JAK) inhibitors for vitiligo, high‐quality evidence and guidelines are lacking. We evaluated the efficacy and safety of JAK inhibitors for the treatment of vitiligo using a meta‐analysis of randomized controlled trials (RCTs). We searched the PubMed, Embase, and Cochrane Library databases up to August 2023, with additional studies from ClinicalTrials.gov and company websites. We assessed outcomes, including percentage improvement in total vitiligo area score index (TVASI) and facial vitiligo area score index (FVASI); the proportion of patients achieving 50% improvement in TVASI (TVASI50) and 50% and 75% improvement in FVASI (FVASI50 and FVASI75); the risk of treatment‐emergent adverse events (TEAEs), serious adverse events (SAEs), infections, and skin‐related adverse events (AEs). Five studies with 1,550 participants were included. JAK inhibitors were associated with a higher proportion of TVASI50 (relative risk [RR] 2.67, 95% confidence interval [CI] 1.24–5.78) and FVASI75 (RR 3.97, 95%CI 2.62–6.02) responders than placebo. JAK inhibitors significantly increased the risk of skin‐related AEs (RR 1.96, 95% CI 1.29–2.98) compared with placebo. However, the risk of TEAEs, SAEs, and infections was not significantly different between the JAK inhibitor and placebo groups. Subgroup analysis showed that JAK1 and JAK1/2 inhibitors were more effective than JAK3 inhibitors. However, there was insufficient evidence to suggest that the route of administration affects the efficacy and safety of JAK inhibitors in vitiligo. These findings indicate that JAK inhibitors are effective in repigmentation and well tolerated in patients with vitiligo.

show abstract

Evaluation of low‐dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: A pilot study

Abstract: prolonged treatment duration may be needed to improve therapeutic efficacy for this patient group. Furthermore, the role of topical Janus kinase inhibitors in treating vitiligo patients who showed inadequate response to previous phototherapy warrants further investigation.

Cited by 8 publications

References 7 publications

Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo

Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo

A review of JAK and IL‐23 inhibitors to treat vitiligo

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About